Loading stock data…
$0.07
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $182,000↓ | $206,000↓ | $256,000↑ | $98,000↓ | $120,000 |
| Gross Profit | $160,000↑ | -$77,000↓ | $224,000↑ | $87,000↑ | $13,000 |
| Operating Income | -$10.19M↑ | -$10.22M↑ | -$10.28M↑ | -$14.03M↑ | -$15.85M |
| Net Income | -$14.71M↓ | -$12.69M↓ | -$12.54M↑ | -$30.91M↓ | -$19.19M |
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United Stat...